SRR934912
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.724047306176084
- age_years
- 63
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.644
- MYC_TARGETS_V1+0.592
- G2M_CHECKPOINT+0.590
- INTERFERON_ALPHA_RESPONSE+0.476
- DNA_REPAIR+0.454
- MYC_TARGETS_V2+0.428
- INTERFERON_GAMMA_RESPONSE+0.423
- OXIDATIVE_PHOSPHORYLATION+0.360
- MTORC1_SIGNALING+0.302
- ANGIOGENESIS+0.290
Top 10 suppressed
- KRAS_SIGNALING_DN-0.374
- MYOGENESIS-0.366
- ESTROGEN_RESPONSE_EARLY-0.322
- HEDGEHOG_SIGNALING-0.320
- APICAL_SURFACE-0.276
- APICAL_JUNCTION-0.267
- WNT_BETA_CATENIN_SIGNALING-0.255
- UV_RESPONSE_DN-0.248
- HEME_METABOLISM-0.218
- ESTROGEN_RESPONSE_LATE-0.204
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934892 | — | — | 0.899 |
| 2 | SRR934927 | — | — | 0.878 |
| 3 | SRR934878 | — | — | 0.868 |
| 4 | 46A44EBC-2B07-45EF-93EF-3F537A8AF49B | — | — | 0.852 |
| 5 | C3N-00294 | — | cohortA1 | 0.846 |
| 6 | 5F350242-0CF6-43AC-AB06-2C130D85C5CC | — | — | 0.844 |
| 7 | MNG726 | — | — | 0.839 |
| 8 | 2E040577-EA0C-4876-9F43-A180DA38F733 | — | — | 0.838 |
| 9 | B1A2365C-5491-4E85-AE7E-97B9DB8FF8D1 | — | — | 0.838 |
| 10 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.644 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.592 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.590 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.476 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.454 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.428 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.423 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.302 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.289 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.234 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.227 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.226 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.212 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.206 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.142 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.134 | Inavolisib | — uncovered |
| APOPTOSIS | 0.117 | Idelalisib | — uncovered |